May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a strategy of early intervention with transcatheter aortic valve replacement (TAVR) compared to other age groups, especially in regards to stroke risk, and in regards to the composite of death, stroke, and heart failure hospitalization. The late-breaking results were presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2025 Scientific Sessions.

At the SCAI 2025 Scientific Sessions in Washington, DC, SCAI President James B. Hermiller, MD, MSCAI, recognized several individuals for their outstanding service, leadership, and contributions to patient care.  

May 1, 2025 – Analyses from the (Ergonomics in the Cardiac Catheterization Laboratory (ERGO-CATH) study show the traditional approach using a lead apron causes 43% of interventional cardiologists to experience discomfort, building on existing consensus of the significant occupational health risks that exist in the catheterization (cath) lab. The data were presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2025 Scientific Sessions in Washington, D.C.

April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, has  announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation (BDD) for atrioventricular interval modulation (AVIM) therapy.

April 25, 2025 – Medtronic plc, a global leader in healthcare technology, recently received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure defibrillation lead for placement within the right ventricle. The lead, built on the highly reliable SelectSecure Model 3830 pacing lead and delivered via catheter, builds on the Medtronic portfolio of lead solutions designed for precise delivery and placement.